Last updated: September 2, 2026
Dacomitinib is a Pfizer EGFR tyrosine kinase inhibitor marketed as Vizimpro for first-line treatment of metastatic non-small-cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitutions. The drug achieved regulatory approval on the strength of progression-free and overall-survival improvements over gefitinib, but its commercial position weakened as osimertinib became the preferred EGFR-directed therapy because of stronger central nervous system activity, adjuvant use, and broader clinical adoption.
Pfizer does not report standalone Vizimpro revenue in its public financial filings. The available financial evidence supports a low-scale, mature oncology product rather than a major growth asset. Future revenue depends mainly on residual use in selected first-line patients, geographic markets where osimertinib access is limited, and physician preference in cases where its efficacy profile remains competitive.
What is dacomitinib and how does Vizimpro work?
Dacomitinib is an irreversible pan-human EGFR-family tyrosine kinase inhibitor. It covalently inhibits EGFR, HER2, and HER4 signaling. Vizimpro tablets are approved in the United States for patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R substitutions, as detected by an FDA-approved test.[1]
Dacomitinib product profile
| Attribute |
Dacomitinib |
| Brand |
Vizimpro |
| Active ingredient |
Dacomitinib |
| Originator |
Pfizer |
| Therapeutic area |
EGFR-mutated metastatic NSCLC |
| FDA approval |
September 27, 2018 |
| Approved line |
First-line metastatic disease |
| Biomarkers |
EGFR exon 19 deletion or exon 21 L858R |
| Dosage form |
Oral tablet |
| Standard dose |
45 mg once daily |
| Principal comparator in registration trial |
Gefitinib |
| Core clinical study |
ARCHER 1050 |
| Key commercial competitor |
Osimertinib, marketed as Tagrisso |
Dacomitinib is not approved for all EGFR mutations. Its labeled population excludes many uncommon EGFR alterations, including exon 20 insertions, and does not make it interchangeable with therapies approved for broader mutation groups.
What clinical evidence supports dacomitinib’s market position?
The pivotal ARCHER 1050 trial enrolled previously untreated patients with EGFR-mutated advanced NSCLC. Dacomitinib improved median progression-free survival to 14.7 months compared with 9.2 months for gefitinib. Median overall survival was 34.1 months with dacomitinib and 26.8 months with gefitinib.[2]
| ARCHER 1050 endpoint |
Dacomitinib |
Gefitinib |
| Median progression-free survival |
14.7 months |
9.2 months |
| Median overall survival |
34.1 months |
26.8 months |
| Hazard ratio for overall survival |
0.748 |
Reference |
| Treatment setting |
First-line |
First-line |
The clinical advantage over gefitinib established dacomitinib as an effective first-generation-to-second-generation EGFR treatment option. Its weakness was tolerability. Common adverse reactions include diarrhea, rash, paronychia, stomatitis, decreased appetite, dry skin, and weight loss. Dose reductions and interruptions are frequent in routine treatment.
How does dacomitinib compare with osimertinib?
Osimertinib has become the principal benchmark for EGFR-mutated NSCLC. The comparison is not based on a direct head-to-head randomized trial between dacomitinib and osimertinib, but on differences in clinical positioning and evidence depth.
| Factor |
Dacomitinib |
Osimertinib |
| Brand |
Vizimpro |
Tagrisso |
| EGFR population |
Exon 19 deletion and L858R |
Broad approved EGFR settings, including exon 19 deletion, L858R, and T790M |
| CNS activity |
More limited clinical positioning |
Strong intracranial efficacy and CNS penetration |
| Adjuvant NSCLC use |
No comparable broad adjuvant role |
Approved after tumor resection in EGFR-mutated NSCLC |
| Major tolerability issue |
Diarrhea, rash, paronychia |
Diarrhea, rash, cardiomyopathy, QT effects, interstitial lung disease risk |
| Commercial status |
Niche first-line product |
Dominant EGFR-directed product |
| Market effect |
Defensive or residual share |
Standard-setting therapy |
The FLAURA trial established osimertinib as a preferred first-line treatment over gefitinib or erlotinib, with median overall survival of 38.6 months versus 31.8 months for the comparator group.[3] The ADAURA trial expanded osimertinib’s commercial and clinical importance by demonstrating disease-free-survival benefits in the adjuvant setting.[4]
When did dacomitinib receive FDA approval and lose regulatory exclusivity?
The FDA approved Vizimpro on September 27, 2018. The approval was based on ARCHER 1050 and required confirmation of EGFR mutation status through an FDA-approved diagnostic test.[1]
Dacomitinib regulatory timeline
| Date |
Event |
| September 27, 2018 |
FDA approval for first-line metastatic EGFR-mutated NSCLC |
| 2018-2023 |
Five-year new chemical entity exclusivity period |
| September 27, 2023 |
Expected end of U.S. NCE exclusivity |
| Post-2023 |
Generic applicants could pursue ANDA filing, subject to patent certification and applicable Orange Book protection |
The five-year NCE exclusivity period blocked FDA approval of an abbreviated new drug application until 2023. It did not prevent patent challenges before that date, and it did not guarantee protection from generic entry after the exclusivity period.
What patents protect dacomitinib and when do they expire?
Dacomitinib’s protection has historically depended on compound patents, related quinazoline chemistry, and potentially formulation or manufacturing claims. The exact commercial protection depends on the patents listed for the relevant product and the effect of patent-term adjustment, patent-term extension, terminal disclaimers, and any later Orange Book amendments.
Public patent records identify Pfizer-associated U.S. patent families covering dacomitinib-related quinazoline compounds. The principal U.S. compound protection was filed well before the 2018 approval and has a term extending into the mid-to-late 2020s, subject to patent-specific adjustments. The five-year NCE period ended in 2023, making patent status the main remaining U.S. barrier to generic approval.
Patent protection categories
| Protection category |
Relevance to Vizimpro |
| Composition of matter |
Covers dacomitinib or related chemical entities |
| Salt and crystal forms |
May cover specific solid-state versions |
| Pharmaceutical composition |
May cover tablet formulations or excipient combinations |
| Manufacturing process |
Can complicate generic API sourcing but usually does not block an alternative process |
| Method of treatment |
May cover treatment of EGFR-mutated NSCLC or dosing regimens |
| Diagnostic-linked use |
May relate to biomarker-selected administration |
The commercially important question is not whether any patent exists, but whether an unexpired, enforceable patent is listed in the Orange Book and can support an injunction or delayed approval. Product-specific expiration dates should be read from the current FDA Orange Book patent listing and the underlying USPTO records rather than inferred from the 2018 approval date.[5]
What is the Orange Book status of Vizimpro?
Vizimpro is an FDA-approved small-molecule prescription drug and is therefore eligible for Orange Book listing. Its generic pathway is an ANDA rather than a biosimilar application. Applicants must demonstrate pharmaceutical equivalence and bioequivalence and must address listed patents through Paragraph I, II, III, or IV certifications.
The practical regulatory position is:
- The NCE exclusivity barrier expired in September 2023.
- Any remaining listed patents determine whether an ANDA can receive immediate approval.
- A Paragraph IV certification could trigger patent litigation if Pfizer or another patent owner files suit within the statutory period.
- Method-of-use patents may be addressable through a section viii statement if the generic label omits the protected use.
- Manufacturing patents generally create less direct market blockage unless the generic product depends on the patented process.
No major publicly disclosed U.S. Paragraph IV settlement involving dacomitinib has established a widely recognized generic launch date. The absence of a public settlement does not mean that no ANDA activity exists; ANDA litigation and commercial filing activity can remain confidential until statutory events occur.
Which companies are challenging dacomitinib’s market position?
The competitive threat comes primarily from other EGFR inhibitors rather than from a disclosed dacomitinib-specific challenger.
Major competitors
- AstraZeneca’s osimertinib, marketed as Tagrisso
- Roche’s erlotinib, marketed as Tarceva
- Novartis’s gefitinib, marketed as Iressa in certain markets
- Boehringer Ingelheim’s afatinib, marketed as Gilotrif or Giotrif
- Generic versions of gefitinib and erlotinib
- Amgen’s amivantamab for selected EGFR exon 20 insertion disease, which is not a direct substitute for dacomitinib’s labeled population
Osimertinib has the strongest strategic position because it combines first-line metastatic use, T790M activity, CNS efficacy, and adjuvant treatment. Generic gefitinib and erlotinib exert price pressure in markets where physicians prioritize low acquisition cost.
How strong is the dacomitinib patent estate?
Dacomitinib’s patent estate is commercially weaker than a recently launched oncology product because its principal regulatory exclusivity has expired and its remaining protection is tied to older patent families.
Strengths
- Composition-of-matter protection historically provided the strongest exclusionary rights.
- The product has a defined biomarker-selected use.
- Oncology treatment value can support litigation even when market share is limited.
- Formulation and process patents may raise development costs for generic applicants.
Weaknesses
- The product launched in 2018, leaving a relatively short commercial window before loss of NCE exclusivity.
- The leading competitor has stronger clinical positioning.
- Treatment toxicity can reduce physician preference and persistence.
- Method-of-use claims may be vulnerable to label carving or validity challenges.
- Process patents usually do not prevent an alternative manufacturing route.
The estate should be classified as a late-life, moderate-to-low commercial protection platform rather than a high-value, broad-spectrum oncology franchise.
What is dacomitinib’s financial trajectory?
Pfizer does not disclose Vizimpro revenue as a separate line item in its annual reports. The company reports revenue by larger therapeutic categories and selected products, but Vizimpro is not identified as a material standalone revenue driver.[6]
Financial trajectory
| Period |
Financial interpretation |
| 2018 launch |
Initial uptake supported by positive ARCHER 1050 data |
| 2019-2021 |
Commercial pressure increased as osimertinib became the preferred EGFR therapy |
| 2022-2023 |
Mature or declining niche product; NCE exclusivity approached expiration |
| 2024 onward |
Greater exposure to generic risk, price pressure, and formulary substitution |
Dacomitinib’s revenue potential was constrained from launch by several factors:
- It entered a market increasingly shaped by osimertinib.
- It lacked an adjuvant indication comparable to Tagrisso.
- Its toxicity profile required active adverse-event management.
- Its labeled mutation population was narrower than the total EGFR-mutated NSCLC market.
- Pfizer’s commercial focus was distributed across a larger oncology portfolio.
Revenue exposure to generic entry
Generic entry would likely reduce net price rapidly if multiple ANDA applicants receive approval. The effect would be greatest in the United States, where patent expiry can produce rapid substitution, and in markets with automatic generic substitution.
A single generic entrant could cause a sharp price decline without eliminating all branded demand. Residual Vizimpro use could persist among physicians who value ARCHER 1050 survival data, patients stable on treatment, or markets where reimbursement policies do not mandate substitution. Multiple generic entrants would produce greater erosion and could make continued promotion economically unattractive.
What generic launch scenarios exist for Vizimpro?
Scenario 1: Patent-delayed entry
An unexpired Orange Book patent or successful litigation could delay ANDA approval. This outcome would preserve a limited branded revenue stream but would not restore Vizimpro’s prior growth prospects.
Scenario 2: First generic approval
The first approved generic could launch at a reduced price, subject to any 180-day exclusivity associated with a successful Paragraph IV challenge. Pfizer could retain some branded demand through contracting, physician familiarity, and supply reliability.
Scenario 3: Multi-generic substitution
Multiple approved generics would place Vizimpro under sustained price and volume pressure. Pharmacy substitution would likely accelerate, especially for new prescriptions.
Scenario 4: Authorized or settlement-based generic
A settlement or authorized generic arrangement could allow earlier controlled entry while preserving some value for the patent holder. No broadly reported settlement has defined the market timetable for dacomitinib.
What manufacturing and intellectual-property barriers affect dacomitinib?
Dacomitinib is an oral small molecule, so manufacturing barriers are lower than for biologics. Generic developers must reproduce the active ingredient, tablet strength, dissolution profile, stability, and bioequivalence characteristics.
Potential barriers include:
- API impurity control
- Solid-state form selection
- Stability in the finished tablet
- Reproducible dissolution
- Scale-up of the chemical synthesis
- Control of process-related impurities
- Patent claims covering specific intermediates or synthetic routes
These issues can delay development but rarely create a durable barrier comparable to the manufacturing complexity of monoclonal antibodies or cell therapies.
What licensing deals and partnerships involve dacomitinib?
Dacomitinib is primarily a Pfizer-originated and Pfizer-commercialized product. No major external licensing transaction has defined its current commercial economics in the manner seen with partnered oncology assets. The key strategic issue is portfolio allocation: Pfizer can maintain availability through its existing infrastructure without relying on a separate licensee, but the company has limited incentive to expand promotion for a mature product facing superior competition.
What patent litigation affects Vizimpro?
No major, market-defining U.S. patent litigation involving Vizimpro has produced a publicly established generic launch date. The principal litigation risk remains prospective ANDA litigation based on Orange Book certifications.
Potential claims would likely involve:
- Compound or chemical-structure patents
- Formulation patents
- Method-of-use claims for EGFR-mutated NSCLC
- Dosing or administration claims
- Patent-term calculations and listing validity
For investors and licensing counterparties, the relevant diligence issue is whether any asserted patent has claims broad enough to cover the generic product and a remaining term long enough to justify litigation expense.
What is the global market outlook for dacomitinib?
Dacomitinib’s geographic value varies substantially.
United States
The U.S. market has the greatest generic-entry risk because the NCE period has expired and generic substitution can rapidly affect price and volume. Commercial value is likely concentrated in residual branded prescribing and any remaining patent-protected interval.
Europe
European sales depend on national reimbursement, health-technology-assessment decisions, and local patent status. Price controls and reference pricing can limit branded returns even before full generic substitution.
Japan and Asia-Pacific
Dacomitinib may retain value in markets where EGFR mutation prevalence is high and access to osimertinib is constrained by reimbursement or pricing. The drug’s benefit over gefitinib remains commercially relevant in treatment systems using cost-effectiveness comparisons against earlier-generation EGFR inhibitors.
Emerging markets
Lower-priced branded versions and local generics may support volume but produce limited Pfizer revenue. Local patent enforcement, regulatory requirements, and procurement tenders determine commercial outcomes.
How does dacomitinib compare with other EGFR inhibitors commercially?
| Drug |
Main commercial advantage |
Main commercial weakness |
| Dacomitinib |
Strong ARCHER 1050 survival result versus gefitinib |
Toxicity and weaker CNS positioning |
| Osimertinib |
CNS efficacy, broad clinical use, adjuvant approval |
High cost and eventual patent exposure |
| Gefitinib |
Generic availability and low cost |
Inferior survival position versus newer agents |
| Erlotinib |
Long clinical history and generic pricing |
Declining relevance in first-line EGFR disease |
| Afatinib |
Irreversible EGFR-family inhibition and broad historical use |
Tolerability and competitive displacement |
Key Takeaways
- Dacomitinib is an effective first-line therapy for EGFR exon 19 deletion or L858R metastatic NSCLC.
- Its pivotal advantage over gefitinib was demonstrated in progression-free and overall survival.
- Osimertinib has displaced dacomitinib as the dominant EGFR-directed treatment because of CNS activity, broader clinical positioning, and adjuvant approval.
- U.S. five-year NCE exclusivity ended on September 27, 2023.
- Remaining commercial protection depends on Orange Book-listed patents and patent-term calculations.
- Pfizer does not disclose standalone Vizimpro revenue, indicating that product-specific financial analysis must rely on market positioning rather than reported sales.
- Generic entry is the largest forward risk, with potential for rapid price erosion after the first approved ANDA.
- Dacomitinib remains more commercially relevant in cost-sensitive markets and selected patients than in premium first-line U.S. oncology practice.
- The patent estate is a late-life asset with moderate legal value but limited strategic growth potential.
FAQs
Is dacomitinib still used after osimertinib?
Yes. Dacomitinib remains an approved option for first-line treatment of metastatic NSCLC with EGFR exon 19 deletions or L858R substitutions, although osimertinib is generally the stronger commercial and clinical competitor.
Can dacomitinib treat EGFR exon 20 insertion mutations?
Dacomitinib is not approved for EGFR exon 20 insertion-positive NSCLC. That population has separate treatment options and requires mutation-specific regulatory assessment.
Does dacomitinib have a biosimilar pathway?
No. Dacomitinib is a synthetic small molecule, so competitors use the ANDA generic pathway rather than the FDA biosimilar pathway.
What is the largest commercial risk to Vizimpro?
The largest risk is generic substitution after expiration or invalidation of applicable patents. Competitive displacement by osimertinib is the largest risk to branded demand before or independent of generic entry.
Why did dacomitinib not become the leading EGFR inhibitor?
Its market share was constrained by significant gastrointestinal and dermatologic toxicity, limited CNS positioning, a narrower approved use profile, and the stronger clinical and commercial adoption of osimertinib.
References
- U.S. Food and Drug Administration. (2018, September 27). FDA approves dacomitinib for metastatic non-small cell lung cancer. https://www.fda.gov
- Mok, T. S., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., Chiu, C. H., Kato, T., Imamura, F., Nishio, M., Watanabe, S., Vansteenkiste, J., Kabraji, S., Soo, R. A., Chen, C., & Hida, T. (2018). Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. Journal of Clinical Oncology, 36(22), 2244-2250.
- Soria, J. C., Ohe, Y., Vansteenkiste, J., ReungReung, P., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., Okamoto, I., Zhou, C., Cho, B. C., Cheng, Y., Cho, E. K., Voon, P. J., Planchard, D., Tsai, C. M., Hodge, R., ... Ramalingam, S. S. (2018). Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. New England Journal of Medicine, 378(2), 113-125.
- Wu, Y. L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., Goldman, J. W., Vu, H. V., Lu, S., Vu, V. V., Laktionov, K., Kim, S. W., Van Schil, P. E., Peters, S., Ren, S., Tiseo, M., de Marinis, F., Li, W., ... Herbst, R. S. (2020). Osimertinib in resected EGFR-mutated non-small-cell lung cancer. New England Journal of Medicine, 383(18), 1711-1723.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov
- Pfizer Inc. (2023). 2023 annual report. https://www.pfizer.com/investor-relations/financial-information/annual-reports
